New program offers early access to cancer drug for patients with limited options
NCT ID NCT06132191
First seen Nov 20, 2025 · Last updated May 24, 2026 · Updated 22 times
Summary
This program provides expanded access to cemiplimab, a cancer drug, for people with non-small cell lung cancer, basal cell carcinoma, or cutaneous squamous cell carcinoma who have no other treatment options. The goal is to make the drug available to those who cannot join a clinical trial. Participants will receive cemiplimab to help control their disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.